Top Stories
The Dresden, Germany facility employs about 640 workers.
The oral, selective PI3Kδ inhibitor is approved for children aged 4 to 11 with activated phosphoinositide 3-kinase delta syndrome (APDS), adding to an earlier clearance for individuals aged 12 and older.
In addition to small molecules, the facility will support the production of biologics and mRNA-based therapies.
The FDA asked for updated safety and efficacy data on the oral kinase inhibitor, extending its review by three months to March 3 of next year.
The oral CGRP inhibitor is the first of its class to successfully reduce migraine days in adults with menstrual migraine.
Conference News
SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pionee...
- New global Phase 1 data from a randomized dose-expansion cohort of iza-bren in previously treated EGFR-mutated metastatic NSCLC demonstrate promising antitumor activity and a tolerable safety profil...
Presidential Symposium to feature final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLCAdditional findings show low rates of key treatment-r...
Kensington, MD, USA and Munich/Martinsried, Germany, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Kensington, MD, USA, and Munich/Martinsried, Germany, September 11, 2026 – Galimedix Therapeutics, Inc. (“Galime...
FirstWord spoke with University College London’s Adam Ioannou about detailed Phase III CARDIO-TTransform data for AZ and Ionis' eplontersen, and what impact the failed study will have on use of TTR silencers and stabilisers to treat ATTR-CM.
